Nurexone Biologic Stock Performance
| NRX Stock | 0.71 0.01 1.43% |
On a scale of 0 to 100, NurExone Biologic holds a performance score of 7. The company secures a Beta (Market Risk) of -1.08, which conveys a somewhat significant risk relative to the market. As the market becomes more bullish, returns on owning NurExone Biologic are expected to decrease slowly. On the other hand, during market turmoil, NurExone Biologic is expected to outperform it slightly. Please check NurExone Biologic's potential upside, as well as the relationship between the kurtosis and day typical price , to make a quick decision on whether NurExone Biologic's current price movements will revert.
Risk-Adjusted Performance
7 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in NurExone Biologic are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, NurExone Biologic showed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | NurExone Biologic to Showcase Exosome Therapies Globally - TipRanks | 09/12/2024 |
2 | NurExone Gains Key EMA Status for ExoPTEN - TipRanks | 11/13/2024 |
| Begin Period Cash Flow | 2.5 M | |
| Free Cash Flow | -3.1 M |
NurExone |
NurExone Biologic Relative Risk vs. Return Landscape
If you would invest 56.00 in NurExone Biologic on September 1, 2024 and sell it today you would earn a total of 15.00 from holding NurExone Biologic or generate 26.79% return on investment over 90 days. NurExone Biologic is currently producing 0.4923% returns and takes up 5.0688% volatility of returns over 90 trading days. Put another way, 45% of traded stocks are less volatile than NurExone, and 91% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
NurExone Biologic Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for NurExone Biologic's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as NurExone Biologic, and traders can use it to determine the average amount a NurExone Biologic's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0971
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | NRX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.07 actual daily | 45 55% of assets are more volatile |
Expected Return
| 0.49 actual daily | 9 91% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 7 93% of assets perform better |
Based on monthly moving average NurExone Biologic is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of NurExone Biologic by adding it to a well-diversified portfolio.
NurExone Biologic Fundamentals Growth
NurExone Stock prices reflect investors' perceptions of the future prospects and financial health of NurExone Biologic, and NurExone Biologic fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NurExone Stock performance.
| Return On Equity | -2.54 | ||||
| Return On Asset | -1.14 | ||||
| Current Valuation | 46.99 M | ||||
| Shares Outstanding | 70.84 M | ||||
| Price To Book | 13.94 X | ||||
| EBITDA | (4.09 M) | ||||
| Net Income | (3.64 M) | ||||
| Total Debt | 1.98 M | ||||
| Book Value Per Share | 0 X | ||||
| Cash Flow From Operations | (2.94 M) | ||||
| Earnings Per Share | (0.11) X | ||||
| Total Asset | 2.17 M | ||||
| Retained Earnings | (14.06 M) | ||||
About NurExone Biologic Performance
Evaluating NurExone Biologic's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if NurExone Biologic has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if NurExone Biologic has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
NurExone Biologic is entity of Canada. It is traded as Stock on V exchange.Things to note about NurExone Biologic performance evaluation
Checking the ongoing alerts about NurExone Biologic for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NurExone Biologic help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| NurExone Biologic had very high historical volatility over the last 90 days | |
| NurExone Biologic has some characteristics of a very speculative penny stock | |
| NurExone Biologic has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (3.64 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| NurExone Biologic generates negative cash flow from operations | |
| Latest headline from news.google.com: NurExone Gains Key EMA Status for ExoPTEN - TipRanks |
- Analyzing NurExone Biologic's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NurExone Biologic's stock is overvalued or undervalued compared to its peers.
- Examining NurExone Biologic's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NurExone Biologic's management team can have a significant impact on its success or failure. Reviewing the track record and experience of NurExone Biologic's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of NurExone Biologic's stock. These opinions can provide insight into NurExone Biologic's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for NurExone Stock Analysis
When running NurExone Biologic's price analysis, check to measure NurExone Biologic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NurExone Biologic is operating at the current time. Most of NurExone Biologic's value examination focuses on studying past and present price action to predict the probability of NurExone Biologic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NurExone Biologic's price. Additionally, you may evaluate how the addition of NurExone Biologic to your portfolios can decrease your overall portfolio volatility.